caa a22 4500 445795425 CHVBK 20180317145123.0 cr unu---uuuuu 170323e20111001xx s 000 0 eng 10.1007/s10620-011-1802-z doi (NATIONALLICENCE)springer-10.1007/s10620-011-1802-z Direct Medical Care Costs Among Pegylated Interferon Plus Ribavirin-Treated and Untreated Chronic Hepatitis C Patients [Elektronische Daten] [M. Solomon, M. Bonafede, K. Pan, K. Wilson, C. Beam, P. Chakravarti, B. Spiegel] Background: Hepatitis C virus (HCV) is a common and expensive infectious disease. The current standard of care for HCV infection, pegylated interferon with ribavirin (PEG-RBV), is costly and has a significant adverse event profile. Aim: To quantify the direct economic burden of HCV infection and PEG-RBV treatment for HCV. Methods: Using a large administrative claims database, we evaluated the medical and prescription drug costs of patients with HCV from 2002 to 2007. A cohort of patients with PEG-RBV was 1:1 propensity score-matched to a cohort of untreated HCV patients. Multivariate models adjusted for demographic and clinical characteristics in evaluating the effect of PEG-RBV treatment on direct medical expenditure. Results: The matched analysis included 20,002 patients. PEG-RBV-treated patients had higher total direct medical costs ($28,547 vs. $21,752; P<0.001), outpatient pharmacy costs ($17,419 vs. $2,900; P<0.001), and outpatient physician visit costs ($894 vs. $787; P<0.001), but lower inpatient costs ($3,942 vs. $9,543; P<0.001) and emergency room costs ($366 vs. $505; P<0.001). After multivariate adjustment, PEG-RBV use was associated with an additional $9,423 in total direct medical costs and an additional $12,244 in HCV-related total medical costs. Conclusion: Total HCV-related medical costs are higher for treated than untreated patients, driven mostly by higher outpatient pharmacy costs, which outweigh higher HCV-related inpatient costs incurred by untreated patients. Springer Science+Business Media, LLC, 2011 Hepatitis C nationallicence Pegylated interferon nationallicence Burden of illness nationallicence Administrative claims database analysis nationallicence Solomon M. Stanford University School of Medicine, Stanford, CA, USA aut Bonafede M. Thomson Reuters Healthcare, Cambridge, MA, USA aut Pan K. Thomson Reuters Healthcare, Cambridge, MA, USA aut Wilson K. Thomson Reuters Healthcare, Cambridge, MA, USA aut Beam C. Human Genome Sciences, Inc, Rockville, MD, USA aut Chakravarti P. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA aut Spiegel B. Department of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA aut Digestive Diseases and Sciences Springer US; http://www.springer-ny.com 56/10(2011-10-01), 3024-3031 0163-2116 56:10<3024 2011 56 10620 https://doi.org/10.1007/s10620-011-1802-z text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10620-011-1802-z text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Solomon M. Stanford University School of Medicine, Stanford, CA, USA aut NATIONALLICENCE 700 1- Bonafede M. Thomson Reuters Healthcare, Cambridge, MA, USA aut NATIONALLICENCE 700 1- Pan K. Thomson Reuters Healthcare, Cambridge, MA, USA aut NATIONALLICENCE 700 1- Wilson K. Thomson Reuters Healthcare, Cambridge, MA, USA aut NATIONALLICENCE 700 1- Beam C. Human Genome Sciences, Inc, Rockville, MD, USA aut NATIONALLICENCE 700 1- Chakravarti P. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA aut NATIONALLICENCE 700 1- Spiegel B. Department of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA aut NATIONALLICENCE 773 0- Digestive Diseases and Sciences Springer US; http://www.springer-ny.com 56/10(2011-10-01), 3024-3031 0163-2116 56:10<3024 2011 56 10620 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer